Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 10(1): 19314, 2020 11 09.
Article in English | MEDLINE | ID: mdl-33168939

ABSTRACT

Achromatopsia is an inherited retinal disease characterized by loss of cone photoreceptor function. Day blind CNGA3 mutant Improved Awassi sheep provide a large animal model for achromatopsia. This study measured refractive error and axial length parameters of the eye in this model and evaluated chromatic pupillary light reflex (cPLR) testing as a potential screening test for loss of cone function. Twenty-one CNGA3 mutant, Improved Awassi, 12 control Afec-Assaf and 12 control breed-matched wild-type (WT) Awassi sheep were examined using streak retinoscopy and B-mode ocular ultrasonography. Four CNGA3 mutant and four Afec-Assaf control sheep underwent cPLR testing. Statistical tests showed that day-blind sheep are significantly more myopic than both Afec-Assaf and WT Awassi controls. Day-blind sheep had significantly longer vitreous axial length compared to WT Awassi (1.43 ± 0.13 and 1.23 ± 0.06 cm, respectively, p < 0.0002) and no response to bright red light compared to both controls. Lack of response to bright red light is consistent with cone dysfunction, demonstrating that cPLR can be used to diagnose day blindness in sheep. Day-blind sheep were found to exhibit myopia and increased vitreous chamber depth, providing a naturally occurring large animal model of myopia.


Subject(s)
Color Vision Defects/diagnosis , Color Vision Defects/physiopathology , Cyclic Nucleotide-Gated Cation Channels/genetics , Myopia/diagnosis , Myopia/physiopathology , Retinal Cone Photoreceptor Cells/physiology , Vision Disorders/diagnosis , Vision Disorders/physiopathology , Animals , Disease Models, Animal , Electroretinography , Female , Light , Male , Mutation , Photoreceptor Cells, Vertebrate/metabolism , Pupil , Refractive Errors , Retina/metabolism , Retinoscopy , Sheep , Sheep, Domestic , Ultrasonography , Vision, Ocular
2.
Invest Ophthalmol Vis Sci ; 58(3): 1577-1584, 2017 03 01.
Article in English | MEDLINE | ID: mdl-28282490

ABSTRACT

Purpose: Applying CNGA3 gene augmentation therapy to cure a novel causative mutation underlying achromatopsia (ACHM) in sheep. Methods: Impaired vision that spontaneously appeared in newborn lambs was characterized by behavioral, electroretinographic (ERG), and histologic techniques. Deep-sequencing reads of an affected lamb and an unaffected lamb were compared within conserved genomic regions orthologous to human genes involved in similar visual impairment. Observed nonsynonymous amino acid substitutions were classified by their deleteriousness score. The putative causative mutation was assessed by producing compound CNGA3 heterozygotes and applying gene augmentation therapy using the orthologous human cDNA. Results: Behavioral assessment revealed day blindness, and subsequent ERG examination showed attenuated photopic responses. Histologic and immunohistochemical examination of affected sheep eyes did not reveal degeneration, and cone photoreceptors expressing CNGA3 were present. Bioinformatics and sequencing analyses suggested a c.1618G>A, p.Gly540Ser substitution in the GMP-binding domain of CNGA3 as the causative mutation. This was confirmed by genetic concordance test and by genetic complementation experiment: All five compound CNGA3 heterozygotes, carrying both p.Arg236* and p.Gly540Ser mutations in CNGA3, were day-blind. Furthermore, subretinal delivery of the intact human CNGA3 gene using an adeno-associated viral vector (AAV) restored photopic vision in two affected p.Gly540Ser homozygous rams. Conclusions: The c.1618G>A, p.Gly540Ser substitution in CNGA3 was identified as the causative mutation for a novel form of ACHM in Awassi sheep. Gene augmentation therapy restored vision in the affected sheep. This novel mutation provides a large-animal model that is valid for most human CNGA3 ACHM patients; the majority of them carry missense rather than premature-termination mutations.


Subject(s)
Carrier Proteins/genetics , Color Vision Defects/therapy , Cyclic Nucleotide-Gated Cation Channels/genetics , DNA/genetics , Genetic Therapy/methods , Intracellular Signaling Peptides and Proteins/genetics , Mutation , Animals , Animals, Newborn , Carrier Proteins/metabolism , Color Vision Defects/diagnosis , Color Vision Defects/genetics , Cyclic Nucleotide-Gated Cation Channels/metabolism , DNA Mutational Analysis , Disease Models, Animal , Electroretinography , Female , Genotype , Homozygote , Immunohistochemistry , Intracellular Signaling Peptides and Proteins/metabolism , Male , Retina/physiopathology , Sheep
SELECTION OF CITATIONS
SEARCH DETAIL
...